TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
TARA

Protara Therapeutics Inc

Healthcare · Biotechnology

2.40$ -2.8% vs. previous close Closing price · As of: Nov 2, 2026

Ownership

Ownership Structure

Who owns Protara Therapeutics Inc (TARA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 92.9% of the shares are freely tradable; institutional investors hold 82.4%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 82.4%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 92.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 10.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 59Mio.

Largest Shareholders

Institutions

Institutions TARA
Name Stake (%) Shares Change (%) Date
HHG PLC 8.81 5,207,011 +1.3 03/31/2026
Jupiter Topco LLC 7.95 4,696,709 +0.0 06/30/2026
BlackRock Inc 6.20 3,663,499 +7.9 06/30/2026
Millennium Management LLC 5.25 3,101,166 +9.5 06/30/2026
Velan Capital Investment Management LP 4.81 2,844,652 +0.4 06/30/2026
Vanguard Capital Management, LLC 3.89 2,300,133 +8.5 06/30/2026
Blackstone Inc 3.83 2,265,514 +0.0 06/30/2026
Orbimed Advisors LLC 3.76 2,220,000 +0.0 06/30/2026
Sio Capital Management, LLC 3.25 1,921,872 -2.4 06/30/2026

Funds

Funds TARA
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.81 1,657,879 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?